TAEUK KANG: Open Payments
NPI 1174125595 · COPPELL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,392 in 108 payments from 28 companies in 2025. Trend: 2023 $0 · 2024 $1,578 · 2025 $2,392
Food & beverage: $2,392
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $306 |
| Otsuka America Pharmaceutical, Inc. | 11 | $268 |
| ABBVIE INC. | 14 | $221 |
| AstraZeneca Pharmaceuticals LP | 8 | $217 |
| GlaxoSmithKline, LLC. | 6 | $193 |
| Lilly USA, LLC | 12 | $188 |
| Merck Sharp & Dohme LLC | 1 | $116 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $107 |
| Astellas Pharma US Inc | 3 | $83 |
| ViiV Healthcare Company | 3 | $80 |
Products named: REXULTI, JARDIANCE, SHINGRIX, BREZTRI, Wegovy, VRAYLAR, Ozempic, CAPVAXIVE.
Industry payments across TX — which companies pay providers there.
